A Twelve-month, Multicenter, Open-label, Randomized Study of the Safety, Tolerability and Efficacy of Everolimus With Basiliximab, Corticosteroids and Two Different Exposure Levels of Tacrolimus in de Novo Renal Transplant Recipients

Autores
Categoría Estudio primario
Registro de estudiosclinicaltrials.gov
Año 2006

Este artículo no está incluido en ninguna revisión sistemática

Cargando información sobre las referencias
This study is designed to evaluate whether tacrolimus dose reduction in de novo renal recipients receiving everolimus can preserve renal function while maintaining efficacy.
Epistemonikos ID: 291f3d893f902218714f338b593cfb11db3d3830
First added on: May 04, 2024